Antipsychotic exposure is an independent risk factor for breast cancer: A systematic review of epidemiological evidence
BackgroundThe effect of antipsychotics on breast cancer remains controversial.Materials and methodsEmbase, Scopus, PubMed, Web of Science, Cochrane Library, and Hebei Medical University Library were used for the literature search. Observational studies with original data for the effects of antipsych...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.993367/full |
| _version_ | 1811177756151513088 |
|---|---|
| author | Zheng Gao Yin Xi Hekai Shi Jiyuan Ni Wei Xu Kaili Zhang |
| author_facet | Zheng Gao Yin Xi Hekai Shi Jiyuan Ni Wei Xu Kaili Zhang |
| author_sort | Zheng Gao |
| collection | DOAJ |
| description | BackgroundThe effect of antipsychotics on breast cancer remains controversial.Materials and methodsEmbase, Scopus, PubMed, Web of Science, Cochrane Library, and Hebei Medical University Library were used for the literature search. Observational studies with original data for the effects of antipsychotics on breast cancer were used. Studies of bed quality, those with inadequate sample size, incomplete follow-up works, or studies that did not meet the criteria were excluded. Meta-analysis was performed using R version 4.1.2. The odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the proportion of breast cancer in different groups. To detect possible sources of heterogeneity, subgroup and meta-regression analyses were employed.ResultsPooled data from 11 relevant studies with 1,499,001 participants suggested that individuals exposed to antipsychotics were more likely to suffer from breast cancer than those who were not exposed (OR, 1.23; 95% CI, 1.04–1.47). No significant difference in breast cancer prevalence between the atypical and typical antipsychotic groups was found (OR, 1.23; 95% CI, 0.93–1.63). Prolactin (PRL)-increasing and PRL-sparing antipsychotics posed a similar risk of breast cancer (OR, 1.13; 95% CI, approximately 0.97–1.31). Furthermore, the use of antipsychotics is attributed to increased mortality in patients with breast cancer (OR, 1.54; 95% CI, 1.29–1.82). Those exposed to antipsychotics at the maximum dose were more likely to suffer from breast cancer than those exposed to the minimum dose.ConclusionsAntipsychotic exposure is an independent risk factor for breast cancer. No significant difference in the risk of breast cancer between typical and atypical antipsychotics was noted. Those exposed to antipsychotics at higher doses are more likely to suffer from breast cancer. Moreover, the use of antipsychotics is attributed to increased mortality in patients with breast cancer. PRL-increasing and PRL-sparing antipsychotics pose a similar risk of breast cancer.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022307624. |
| first_indexed | 2024-04-11T06:07:48Z |
| format | Article |
| id | doaj.art-8dce102359924854ad23b05537874679 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T06:07:48Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8dce102359924854ad23b055378746792022-12-22T04:41:28ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.993367993367Antipsychotic exposure is an independent risk factor for breast cancer: A systematic review of epidemiological evidenceZheng Gao0Yin Xi1Hekai Shi2Jiyuan Ni3Wei Xu4Kaili Zhang5Department of Cardiology, The First Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Internal Medicine, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Internal Medicine, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Orthopedics, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Internal Medicine, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment Of Adenosurgery, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaBackgroundThe effect of antipsychotics on breast cancer remains controversial.Materials and methodsEmbase, Scopus, PubMed, Web of Science, Cochrane Library, and Hebei Medical University Library were used for the literature search. Observational studies with original data for the effects of antipsychotics on breast cancer were used. Studies of bed quality, those with inadequate sample size, incomplete follow-up works, or studies that did not meet the criteria were excluded. Meta-analysis was performed using R version 4.1.2. The odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the proportion of breast cancer in different groups. To detect possible sources of heterogeneity, subgroup and meta-regression analyses were employed.ResultsPooled data from 11 relevant studies with 1,499,001 participants suggested that individuals exposed to antipsychotics were more likely to suffer from breast cancer than those who were not exposed (OR, 1.23; 95% CI, 1.04–1.47). No significant difference in breast cancer prevalence between the atypical and typical antipsychotic groups was found (OR, 1.23; 95% CI, 0.93–1.63). Prolactin (PRL)-increasing and PRL-sparing antipsychotics posed a similar risk of breast cancer (OR, 1.13; 95% CI, approximately 0.97–1.31). Furthermore, the use of antipsychotics is attributed to increased mortality in patients with breast cancer (OR, 1.54; 95% CI, 1.29–1.82). Those exposed to antipsychotics at the maximum dose were more likely to suffer from breast cancer than those exposed to the minimum dose.ConclusionsAntipsychotic exposure is an independent risk factor for breast cancer. No significant difference in the risk of breast cancer between typical and atypical antipsychotics was noted. Those exposed to antipsychotics at higher doses are more likely to suffer from breast cancer. Moreover, the use of antipsychotics is attributed to increased mortality in patients with breast cancer. PRL-increasing and PRL-sparing antipsychotics pose a similar risk of breast cancer.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022307624.https://www.frontiersin.org/articles/10.3389/fonc.2022.993367/fullbreast cancerantipsychoticsrisk factoratypical antipsychoticsprolactin-increasing antipsychotics |
| spellingShingle | Zheng Gao Yin Xi Hekai Shi Jiyuan Ni Wei Xu Kaili Zhang Antipsychotic exposure is an independent risk factor for breast cancer: A systematic review of epidemiological evidence Frontiers in Oncology breast cancer antipsychotics risk factor atypical antipsychotics prolactin-increasing antipsychotics |
| title | Antipsychotic exposure is an independent risk factor for breast cancer: A systematic review of epidemiological evidence |
| title_full | Antipsychotic exposure is an independent risk factor for breast cancer: A systematic review of epidemiological evidence |
| title_fullStr | Antipsychotic exposure is an independent risk factor for breast cancer: A systematic review of epidemiological evidence |
| title_full_unstemmed | Antipsychotic exposure is an independent risk factor for breast cancer: A systematic review of epidemiological evidence |
| title_short | Antipsychotic exposure is an independent risk factor for breast cancer: A systematic review of epidemiological evidence |
| title_sort | antipsychotic exposure is an independent risk factor for breast cancer a systematic review of epidemiological evidence |
| topic | breast cancer antipsychotics risk factor atypical antipsychotics prolactin-increasing antipsychotics |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.993367/full |
| work_keys_str_mv | AT zhenggao antipsychoticexposureisanindependentriskfactorforbreastcancerasystematicreviewofepidemiologicalevidence AT yinxi antipsychoticexposureisanindependentriskfactorforbreastcancerasystematicreviewofepidemiologicalevidence AT hekaishi antipsychoticexposureisanindependentriskfactorforbreastcancerasystematicreviewofepidemiologicalevidence AT jiyuanni antipsychoticexposureisanindependentriskfactorforbreastcancerasystematicreviewofepidemiologicalevidence AT weixu antipsychoticexposureisanindependentriskfactorforbreastcancerasystematicreviewofepidemiologicalevidence AT kailizhang antipsychoticexposureisanindependentriskfactorforbreastcancerasystematicreviewofepidemiologicalevidence |